Latest news with #TranscatheterAorticValveReplacement
Yahoo
23-05-2025
- Business
- Yahoo
Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock
At the EuroPCR 2025, Edwards Lifesciences EW has announced new economic and clinical evidence on severe aortic stenosis (AS). The results of a new real-world study, comprising more than 24,000 patients, demonstrated that intervening on the disease before symptoms develop reduces the economic and resource burden on the healthcare system and improves patient outcomes. Presented as a late-breaking clinical trial, the data further contributes to the extensive body of research on this disease. The development is expected to boost both the company's Transcatheter Aortic Valve Replacement ('TAVR') and Surgical Structural Heart business units. Yesterday, Edwards shares finished the session at $74.79, down 1.7% from the previous close. On a promising note, the company has been committed to TAVR innovation and high-quality science that is increasing access to treatment options for all AS patients. Robust clinician adoption of the SAPIEN technology backs the segment's growth. In Surgical, Edwards continues to benefit from the strong uptake of the premium RESILIA portfolio, including INSPIRIS, MITRIS and KONECT. The company has been steadily advancing its top-tier surgical innovations around the world, solidifying its position. Hence, we expect that the market sentiment around EW stock will remain positive, driven by the latest news. Irvine, CA-based Edwards Lifesciences boasts a market capitalization of $44.64 billion. The company's earnings yield of 3.2% favorably compares to the industry's -2.8% yield. It has delivered an earnings beat of 3.5%, on average, in the trailing four quarters. The study revealed that prompt intervention for severe AS patients before symptoms developed has resulted in $36,000 less cost per patient for the healthcare system in one year. The length of hospital stay during treatment is shorter by 2.2 days, while follow-up heart failure hospitalizations one year after treatment also dropped by 80%. Additionally, compared with asymptomatic severe AS, delaying treatment until the disease progressed led to a more than seven times higher rate of death within one year after aortic valve replacement (AVR). Image Source: Zacks Investment Research Together with the previous data from the EARLY TAVR trial, these results have reinforced the value of early referral and evaluation by a Heart Valve Team for all patients with severe AS. Per a Market Research Future report, the AS treatment market is estimated at $8.6 billion in 2024 and projected to witness a compound annual growth rate (CAGR) of 7.4% by 2034. The market growth is highly driven by the advancements in medical technology, including minimally invasive procedures and breakthrough devices. Furthermore, the growing awareness among healthcare professionals and patients about treatment options is also leading to the market's expansion as more individuals seek early intervention for their conditions. This month, Edwards received FDA approval for its TAVR therapy, the SAPIEN 3 platform, meant for severe AS patients without symptoms. The approval is based on the groundbreaking data from the EARLY TAVR trial, which demonstrated that asymptomatic severe AS patients randomized to Edwards TAVR experienced superior outcomes compared to guideline-recommended clinical surveillance. In April, the company's SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic (moderate-to-severe or severe) mitral regurgitation (MR) who are deemed unsuitable for surgery or transcatheter edge-to-edge (TEER) therapy. In the past six months, shares of EW have risen 5% against the industry's 11.8% fall. Edwards currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space include Phibro Animal Health PAHC, Hims & Hers Health HIMS and Prestige Consumer Healthcare PBH. While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Hims & Hers Health and Prestige Consumer Health each carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Estimates for Phibro Animal Health's fiscal 2025 earnings per share have jumped 3.6% to $2.01 in the past 30 days. Shares of the company have rallied 24.1% in the past year compared with the industry's 8.6% growth. Its earnings yield of 8.7% compares comfortably with the industry's 0.5% yield. PAHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%. Hims & Hers Health shares have rallied 217.1% in the past year. Estimates for the company's 2025 earnings per share have jumped 12.5% to 72 cents in the past 30 days. HIMS' earnings beat estimates twice in the trailing four quarters, matched in one and missed on another occasion, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%. Estimates for Prestige Consumer Healthcare'sfiscal 2026 earnings per share have increased 1 cent to $4.77 in the past 30 days. Shares of the company have jumped 36.8% in the past year compared with the industry's 10.8% growth. PBH's earnings surpassed estimates in three of the trailing four quarters and matched on one occasion, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 1.5%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report Prestige Consumer Healthcare Inc. (PBH) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
10-02-2025
- Business
- Yahoo
Heart Valve Devices Market Outlook: USD 38.2 Billion by 2034, Expanding at 11.7% CAGR with Rising Cardiovascular Cases
The Heart Valve Devices Market is driven by advancements in aortic, mitral, tricuspid, and pulmonary valve technologies. It includes biological and mechanical valves, catering to the rising demand for minimally invasive procedures. Increasing cardiovascular diseases and aging populations fuel market growth. The report analyzes industry size, share, trends, and forecasts from 2024 to 2034. Wilmington, Delaware, United States, Transparency Market Research Inc., Feb. 10, 2025 (GLOBE NEWSWIRE) -- The global heart valve devices market (mercado de dispositivos de válvula cardíaca) is projected to grow at a robust CAGR of 11.7% during the forecast period, driven by the rising prevalence of cardiovascular diseases and advancements in minimally invasive heart valve replacement procedures. The market, valued at approximately USD 10.9 billion in 2023, is anticipated to reach USD 38.2 billion by 2034. The heart valve devices industry is characterized by intense competition and rapid technological advancements. Key players are actively investing in research and development to create next-generation devices that improve patient outcomes. Regulatory frameworks such as the FDA's Breakthrough Devices Program have facilitated the approval of innovative solutions, accelerating market growth. Request for sample copy of report: Players: Medtronic plc Boston Scientific Corporation Abbott Edwards Lifesciences Corporation Foldax Inc. Novostia SA Meril Life Sciences Pvt. Ltd. Corcym UK Limited JenaValve Technology, Inc. Micro Interventional Devices, Inc. Auto Tissue Berlin GmbH Anteris Technologies Ltd Thubrikar Aortic Valve, Inc. MicroPort Scientific Corporation Biosensors International Group, Ltd. Minimally invasive procedures, such as Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral Valve Repair (TMVR), are gaining traction due to reduced recovery times and lower procedural risks compared to traditional open-heart surgeries. The market's growth is further supported by ongoing clinical trials and regulatory approvals, ensuring a steady influx of novel products. Key Strategies of Market Leaders Investment in Research and Development Top companies are investing heavily in developing new heart valve technologies that improve patient safety, reduce complications, and enhance device longevity. Strategic Acquisitions and Collaborations Companies are acquiring smaller firms and forming partnerships to expand their portfolios and enter new markets. For example, larger companies often acquire startups specializing in next-generation heart valve devices. Geographic Expansion Leading players are expanding into emerging markets such as China, India, and Brazil, where the demand for cardiovascular treatments is rising due to increasing healthcare infrastructure. Regulatory Approvals and Clinical Trials To ensure product safety and effectiveness, companies are conducting clinical trials and securing approvals from regulatory bodies such as the FDA and European Medicines Agency before launching new devices. Key Growth Drivers Rising Prevalence of Heart Diseases Heart valve disorders are becoming more common due to aging populations, unhealthy lifestyles, and increasing cases of diabetes and high blood pressure. This has increased the demand for effective treatment solutions, boosting market growth. Advancements in Minimally Invasive Procedures Traditional open-heart surgeries come with risks and long recovery periods. However, minimally invasive techniques like transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (TMVR) offer safer alternatives, leading to higher adoption rates. Increasing Geriatric Population Older adults are more prone to heart valve diseases. With the global population aging rapidly, the demand for heart valve devices is expected to grow significantly. Technological Innovations Companies are developing next-generation heart valve devices with improved durability, better biocompatibility, and enhanced performance. Innovations such as biodegradable and tissue-engineered heart valves are shaping the future of the market. Favorable Government Initiatives and Healthcare Policies Many governments and healthcare organizations are promoting heart health programs and funding research in cardiovascular treatments. Supportive policies and reimbursement plans encourage patients to opt for advanced heart valve procedures. Unlock Growth Potential in Your Industry! Download PDF Brochure: Top Market Trends Adoption of AI and IoT in Heart Valve Devices: Artificial intelligence is being integrated into heart valve devices to enhance precision and patient monitoring. Emerging Markets: Developing countries are investing in healthcare infrastructure, creating lucrative opportunities for heart valve device manufacturers. Focus on Personalized Medicine: Tailored valve solutions based on individual patient anatomy and needs are gaining traction. Overall Industry Insights The heart valve devices industry is part of the broader cardiovascular devices market, which includes diagnostic tools, monitoring equipment, and therapeutic devices. Innovations in materials science, such as the use of biocompatible polymers and nanotechnology, are transforming the industry. The increasing prevalence of lifestyle diseases, coupled with rising healthcare awareness, continues to drive the market forward. Market Segmentation Type of Heart Valve Aortic Valve Less than 20 mm 20-23 mm 23-26 mm More than 26 mm Mitral Valve Less than 26 mm 26-28 mm 29-31 mm More than 31 mm Tricuspid Valve Pulmonary Valve Material Biological Valves TAVI Surgical Others Mechanical Valves Age Group Pediatric Patients Adults Geriatric Patients End-user Hospitals Ambulatory Surgical Centers Others By Region: North America Europe Asia Pacific Latin America Middle East & Africa North America held the largest market share in 2022, driven by high healthcare expenditure, advanced healthcare infrastructure, and a large patient pool. The Asia Pacific region is anticipated to witness the fastest growth, attributed to increasing healthcare investments and awareness campaigns. Market Outlook and Future Prospects The heart valve devices market is expected to grow steadily over the next decade, driven by technological advancements, increasing awareness, and better access to healthcare. Innovations in biodegradable and smart heart valves will further accelerate market expansion. The global heart valve devices market is projected to reach billions of dollars in revenue over the next few years. The increasing preference for minimally invasive procedures will shape future market trends. Emerging markets will become key contributors as healthcare systems improve worldwide. Buy this Premium Research Report: Why This Report is Useful for Decision-Makers and Investors Comprehensive Market Insights – Helps stakeholders understand the current trends and growth potential of the heart valve devices industry. Investment Guidance – Identifies high-growth segments and emerging opportunities for investors. Strategic Business Planning – Provides key data for companies looking to expand or introduce new products. Competitive Analysis – Offers a detailed look at the strategies of top market players. More Trending Reports by Transparency Market Research – Dental Suction Mirror Market (치과 흡입 거울 시장) -The global industry was valued at US$ 49.9 Mn in 2021 and it is projected to grow at a CAGR of 4.8% from 2022 to 2031 and reach more than US$ 79.2 Million by 2031 Wireless Intraoral Camera Market (무선 구강내 카메라 시장) - The global industry was valued at US$ 184.0 Mn in 2021 and It is projected to advance at a CAGR of 9.7% from 2022 to 2031 and reach more than US$ 466.0 Million by 2031 Pediatric Perfusion Products Market (سوق منتجات تروية الأطفال) - The industry was valued at US$ 147.0 Mn in 2021 and it is projected to advance at a CAGR of 7.3% from 2022 to 2031 and reach more than US$ 294.6 Million by the end of 2031 About Transparency Market Research Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. Contact: Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Website: Email: sales@ Follow Us: LinkedIn| Twitter| Blog | YouTube
